Alcohol Withdrawal Clinical Trial
This study is complementary to the main study "Brain Derived Neurotrophic Factor Serum
Levels Evolution During the Six Months After Alcohol Withdrawal " NCT01491347.
Liver stiffness variation is one of the major somatic effect of chronic alcohol consumption.
It is a consequence of numerous mechanisms, including inflammation. Liver stiffness seems to
depend on alcohol consumption in alcohol dependent patient, more precisely on the time after
the last alcohol consumption. This is very few documented after alcohol withdrawal, and has
never been explored during several months after withdrawal as a function of alcohol
consumption and abstinence.
Brain Derived neurotrophic Factor (BDNF) seems to play a major role in general homeostasis
and also liver function.
We propose here to analyse the serum BDNF levels variations after withdrawal according to
liver stiffness levels and alcohol consumption status.
We will also measure liver stiffness using Fibroscan® in alcohol dependent subjects included
in the main study to search for a link with serum BDNF levels and abstinence at day 0, 14,
28 and months 2, 4, and 6.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03916939 -
Osteopathic Treatment to Alcohol Withdrawal Syndrome
|
N/A | |
Completed |
NCT04858490 -
Remote Treatment of Alcohol Withdrawal
|
N/A | |
Not yet recruiting |
NCT04997330 -
Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction
|
N/A | |
Recruiting |
NCT04876443 -
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
|
||
Completed |
NCT05131334 -
Auricular Vagal Stimulation in Alcohol Craving
|
N/A | |
Completed |
NCT02349477 -
Gabapentin for Alcohol Relapse Prevention
|
Phase 2 | |
Terminated |
NCT01937364 -
Preventing Alcohol Withdrawal With Oral Baclofen
|
Phase 2 | |
Completed |
NCT05393544 -
Digitally Assisted Recovery Coach
|
N/A | |
Completed |
NCT00523185 -
A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
|
N/A | |
Completed |
NCT01573052 -
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
|
Phase 4 | |
Enrolling by invitation |
NCT06173973 -
Effects of Ketone Supplementation on Acute Alcohol Withdrawal
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03737864 -
NCARE, Transition to Recovery
|
N/A | |
Recruiting |
NCT03878225 -
Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans?
|
N/A | |
Terminated |
NCT03586089 -
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
|
N/A | |
Recruiting |
NCT04156464 -
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
|
Phase 4 | |
Completed |
NCT02251912 -
Oxytocin Treatment of Alcohol Dependence
|
Phase 2 | |
Completed |
NCT01212185 -
Oxytocin Treatment of Alcohol Withdrawal
|
Phase 1 | |
Recruiting |
NCT04793685 -
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04159909 -
Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal
|
N/A | |
Completed |
NCT05563350 -
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
|